Brief: Mei Pharma And Kyowa Kirin Announce First Patient Dosed In Phase 3 Study Of Zandelisib Plus Rituximab In Non Hodgkin's B-Cell Lymphoma

Kyowa Kirin

17/08/2021 13:19

Aug 17 (Reuters) - Kyowa Kirin Co Ltd  4151.T :
    * MEI PHARMA AND KYOWA KIRIN ANNOUNCE FIRST PATIENT DOSED IN
THE
PHASE 3 COASTAL STUDY EVALUATING ZANDELISIB PLUS RITUXIMAB IN
RELAPSED OR REFRACTORY INDOLENT NON HODGKIN'S B-CELL LYMPHOMA

Source text for Eikon:  ID:nPn8SHXPLa 
Further company coverage:  4151.T 

 ((Reuters.Briefs@thomsonreuters.com;))